Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Drug companies 'not happy' that drug prices 'are going down,' Trump tweets » 10:00
08/13/20
08/13
10:00
08/13/20
10:00
JNJ

Johnson & Johnson

$148.16 /

-1.5 (-1.00%)

, LLY

Eli Lilly

$151.07 /

-0.04 (-0.03%)

, MRK

Merck

$82.53 /

-0.19 (-0.23%)

, PFE

Pfizer

$38.03 /

-0.31 (-0.81%)

, SNY

Sanofi

$51.33 /

-0.55 (-1.06%)

, AZN

AstraZeneca

$56.22 /

+0.37 (+0.66%)

, GSK

GlaxoSmithKline

$41.37 /

+0.1878 (+0.46%)

, NVS

Novartis

$85.50 /

+0.575 (+0.68%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, BMY

Bristol-Myers

$63.19 /

-0.44 (-0.69%)

President Donald Trump…

President Donald Trump tweeted: "Drug companies, which are being forced by me to substantially reduce Drug Prices, are taking $millions in ads saying I want to increase Medicare Primiums. Wrong, just the opposite! These ads show DRUG PRICES ARE GOING DOWN, and they are not happy! False advertising!" Large cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Reference Link

ShowHide Related Items >><<
SNY Sanofi
$51.33 /

-0.55 (-1.06%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.03 /

-0.31 (-0.81%)

NVS Novartis
$85.50 /

+0.575 (+0.68%)

MRK Merck
$82.53 /

-0.19 (-0.23%)

LLY Eli Lilly
$151.07 /

-0.04 (-0.03%)

JNJ Johnson & Johnson
$148.16 /

-1.5 (-1.00%)

GSK GlaxoSmithKline
$41.37 /

+0.1878 (+0.46%)

BMY Bristol-Myers
$63.19 /

-0.44 (-0.69%)

AZN AstraZeneca
$56.22 /

+0.37 (+0.66%)

JNJ Johnson & Johnson
$148.16 /

-1.5 (-1.00%)

07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/29/20 Laidlaw
Curis initiated with a Buy at Laidlaw
07/17/20 Goldman Sachs
J&J valuation discount to S&P 500 'too wide,' says Goldman Sachs
07/17/20 Citi
Johnson & Johnson price target raised to $170 from $165 at Citi
LLY Eli Lilly
$151.07 /

-0.04 (-0.03%)

07/31/20 Barclays
Eli Lilly earnings selloff 'meaningful over-reaction,' says Barclays
07/15/20 H.C. Wainwright
Blueprint Medicines price target raised to $110 from $66 at H.C. Wainwright
07/14/20 Baird
Blueprint Medicines price target raised to $100 from $90 at Baird
07/14/20 Raymond James
Blueprint Medicines price target raised to $106 from $95 at Raymond James
MRK Merck
$82.53 /

-0.19 (-0.23%)

08/11/20 H.C. Wainwright
Pfenex acquisition fits well with Ligand growing portfolio, says H.C. Wainwright
08/04/20 Piper Sandler
Merck deal sparks interest in GLP-1:glucagon agonists, says Piper Sandler
08/03/20
Fly Intel: Top five analyst upgrades
08/03/20 Goldman Sachs
Merck upgraded to Buy from Neutral at Goldman Sachs
PFE Pfizer
$38.03 /

-0.31 (-0.81%)

08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/30/20 Morgan Stanley
Pfizer price target raised to $42 from $36 at Morgan Stanley
07/30/20 Mizuho
Pfizer price target raised to $43 from $38 at Mizuho
SNY Sanofi
$51.33 /

-0.55 (-1.06%)

08/10/20 SVB Leerink
Principia Biopharma price target raised to $112 from $80 at SVB Leerink
07/31/20 JPMorgan
Sanofi price target raised to EUR 106 from EUR 103 at JPMorgan
07/20/20 BMO Capital
Immunic initiated with an Outperform at BMO Capital
07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
AZN AstraZeneca
$56.22 /

+0.37 (+0.66%)

07/31/20 Barclays
Barclays backs Overweight on AstraZeneca after Q2 results
07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
GSK GlaxoSmithKline
$41.37 /

+0.1878 (+0.46%)

08/12/20 UBS
GlaxoSmithKline price target lowered to 1,800 GBp from 1,920 GBp at UBS
07/31/20 Barclays
Barclays backs Underweight on GSK after 'challenging' Q2
07/30/20 Roth Capital
Roth Capital bullish on Ideaya as GSK highlights synthetic lethality pipeline
07/13/20 UBS
UBS reiterates Buy on GSK as FDA belantamab docs are out
NVS Novartis
$85.50 /

+0.575 (+0.68%)

08/12/20 JPMorgan
Novartis price target lowered to CHF 82 from CHF 84 at JPMorgan
07/28/20 Morgan Stanley
Novartis price target raised to CHF 93 from CHF 91 at Morgan Stanley
07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
RHHBY Roche
$0.00 /

+ (+0.00%)

07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
07/24/20 Credit Suisse
Credit Suisse backs Neutral on Roche after H1 results
07/24/20 UBS
Roche Q2 sales weak but recovery in June is evident, says UBS
BMY Bristol-Myers
$63.19 /

-0.44 (-0.69%)

08/06/20 Citi
Investors can refocus on Bristol-Myers story after Eliquis win, says Citi
07/28/20 Mizuho
Wait for Bristol-Myers' bb2121 submission making some 'nervous,' says Mizuho
07/28/20
Fly Intel: Top five analyst initiations
07/28/20 Raymond James
Bristol-Myers initiated with an Outperform at Raymond James
SNY Sanofi
$51.33 /

-0.55 (-1.06%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.03 /

-0.31 (-0.81%)

NVS Novartis
$85.50 /

+0.575 (+0.68%)

MRK Merck
$82.53 /

-0.19 (-0.23%)

LLY Eli Lilly
$151.07 /

-0.04 (-0.03%)

JNJ Johnson & Johnson
$148.16 /

-1.5 (-1.00%)

GSK GlaxoSmithKline
$41.37 /

+0.1878 (+0.46%)

BMY Bristol-Myers
$63.19 /

-0.44 (-0.69%)

AZN AstraZeneca
$56.22 /

+0.37 (+0.66%)

SNY Sanofi
$51.33 /

-0.55 (-1.06%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.03 /

-0.31 (-0.81%)

NVS Novartis
$85.50 /

+0.575 (+0.68%)

MRK Merck
$82.53 /

-0.19 (-0.23%)

LLY Eli Lilly
$151.07 /

-0.04 (-0.03%)

JNJ Johnson & Johnson
$148.16 /

-1.5 (-1.00%)

GSK GlaxoSmithKline
$41.37 /

+0.1878 (+0.46%)

AZN AstraZeneca
$56.22 /

+0.37 (+0.66%)

SNY Sanofi
$51.33 /

-0.55 (-1.06%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NVS Novartis
$85.50 /

+0.575 (+0.68%)

MRK Merck
$82.53 /

-0.19 (-0.23%)

LLY Eli Lilly
$151.07 /

-0.04 (-0.03%)

JNJ Johnson & Johnson
$148.16 /

-1.5 (-1.00%)

BMY Bristol-Myers
$63.19 /

-0.44 (-0.69%)

AZN AstraZeneca
$56.22 /

+0.37 (+0.66%)

SNY Sanofi
$51.33 /

-0.55 (-1.06%)

PFE Pfizer
$38.03 /

-0.31 (-0.81%)

NVS Novartis
$85.50 /

+0.575 (+0.68%)

MRK Merck
$82.53 /

-0.19 (-0.23%)

LLY Eli Lilly
$151.07 /

-0.04 (-0.03%)

JNJ Johnson & Johnson
$148.16 /

-1.5 (-1.00%)

GSK GlaxoSmithKline
$41.37 /

+0.1878 (+0.46%)

BMY Bristol-Myers
$63.19 /

-0.44 (-0.69%)

AZN AstraZeneca
$56.22 /

+0.37 (+0.66%)

Hot Stocks
Genentech: FDA accepts sBLA for self-administration option for Xolair » 05:18
08/13/20
08/13
05:18
08/13/20
05:18
RHHBY

Roche

$0.00 /

+ (+0.00%)

Genentech, a member of…

Genentech, a member of the Roche Group said in a release, "the FDA accepted the company's supplemental Biologics License Application, or sBLA, for a new self-administration option for Xolair across all approved U.S. indications. If approved, Xolair prefilled syringe would become available for either self-administration by select patients or administration by their caregivers. A decision on approval is anticipated by Q1 2021. In the U.S., Xolair is currently approved for administration by a healthcare provider in a healthcare setting, and is the only approved biologic designed to target and block immunoglobulin E, or IgE for the treatment of patients with moderate to severe persistent allergic asthma and chronic idiopathic urticaria, or CIU."

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
07/24/20 Credit Suisse
Credit Suisse backs Neutral on Roche after H1 results
07/24/20 UBS
Roche Q2 sales weak but recovery in June is evident, says UBS
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

Conference/Events
UBS to hold a virtual conference » 04:55
08/13/20
08/13
04:55
08/13/20
04:55
ADPT

Adaptive Biotechnologies

$38.34 /

+1.56 (+4.24%)

, BX

Blackstone

$52.85 /

+0.38 (+0.72%)

, BDX

Becton Dickinson

$257.24 /

+2.24 (+0.88%)

, GH

Guardant Health

$86.82 /

+5.17 (+6.33%)

, ILMN

Illumina

$344.15 /

+3.03 (+0.89%)

, MASI

Masimo

$211.09 /

+1.56 (+0.74%)

, NVTA

Invitae

$29.76 /

+0.775 (+2.67%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, TNDM

TNDM

/

+

, TWST

Twist Bioscience

$62.31 /

+6.72 (+12.09%)

, TXG

10x Genomics

$97.75 /

+0.97 (+1.00%)

Genomics 2.0 Virtual…

Genomics 2.0 Virtual Conference will be held on August 11-13.Webcast Link

ShowHide Related Items >><<
TXG 10x Genomics
$97.75 /

+0.97 (+1.00%)

TWST Twist Bioscience
$62.31 /

+6.72 (+12.09%)

TNDM TNDM
/

+

RHHBY Roche
$0.00 /

+ (+0.00%)

NVTA Invitae
$29.76 /

+0.775 (+2.67%)

MASI Masimo
$211.09 /

+1.56 (+0.74%)

ILMN Illumina
$344.15 /

+3.03 (+0.89%)

GH Guardant Health
$86.82 /

+5.17 (+6.33%)

BX Blackstone
$52.85 /

+0.38 (+0.72%)

BDX Becton Dickinson
$257.24 /

+2.24 (+0.88%)

ADPT Adaptive Biotechnologies
$38.34 /

+1.56 (+4.24%)

ADPT Adaptive Biotechnologies
$38.34 /

+1.56 (+4.24%)

06/18/20 Guggenheim
Adaptive to benefit from increased MRD testing by oncologists, says Guggenheim
06/03/20
Fly Intel: Top five analyst initiations
06/03/20 Goldman Sachs
Adaptive Biotechnologies initiated with a Buy at Goldman Sachs
05/19/20 Guggenheim
Adaptive Biotechnologies price target raised to $50 from $44 at Guggenheim
BX Blackstone
$52.85 /

+0.38 (+0.72%)

06/25/20
Fly Intel: Top five analyst initiations
06/25/20 UBS
Blackstone initiated with a Buy at UBS
06/08/20 Citi
Citi downgrades Alternative Asset Managers to Market Weight, lowers four ratings
06/08/20 Citi
Blackstone downgraded to Neutral from Buy at Citi
BDX Becton Dickinson
$257.24 /

+2.24 (+0.88%)

08/07/20 Raymond James
Becton Dickinson price target raised to $285 from $265 at Raymond James
07/09/20
Fly Intel: Top five analyst upgrades
07/09/20 Barclays
Barclays upgrades Becton Dickinson to Overweight on 'window of opportunity'
07/09/20 Barclays
Becton Dickinson upgraded to Overweight from Equal Weight at Barclays
GH Guardant Health
$86.82 /

+5.17 (+6.33%)

08/10/20 Canaccord
Guardion Health Sciences FDA approval landmark event, says Canaccord
06/12/20
Fly Intel: Top five analyst initiations
06/12/20 BTIG
BTIG starts genomic profiling test 'pioneer' Guardant Health at Buy
06/11/20 BTIG
Guardant Health initiated with a Buy at BTIG
ILMN Illumina
$344.15 /

+3.03 (+0.89%)

08/07/20
Fly Intel: Top five analyst downgrades
08/07/20 Evercore ISI
Illumina downgraded to Underperform from In Line at Evercore ISI
08/07/20 Piper Sandler
Illumina downgraded to Neutral from Overweight at Piper Sandler
07/07/20 Guggenheim
Illumina downgraded to Neutral following 81% rise off lows at Guggenheim
MASI Masimo
$211.09 /

+1.56 (+0.74%)

04/20/20
Fly Intel: Top five analyst downgrades
04/20/20 Needham
Masimo downgraded to Hold from Buy at Needham
04/20/20 Needham
Masimo downgraded to Hold from Buy at Needham
03/02/20 Raymond James
Masimo 'well positioned' should COVID-19 expand, says Raymond James
NVTA Invitae
$29.76 /

+0.775 (+2.67%)

08/05/20 SVB Leerink
Invitae price target lowered to $34 from $40 at SVB Leerink
08/05/20 Ladenburg
Invitae price target raised to $37.25 from $31.25 at Ladenburg
07/22/20 Oppenheimer
Invitae price target raised to $37 from $29 at Oppenheimer
07/01/20 Benchmark
Benchmark says Invitae 'ahead of itself,' downgrades to Hold after run-up
RHHBY Roche
$0.00 /

+ (+0.00%)

07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
07/24/20 Credit Suisse
Credit Suisse backs Neutral on Roche after H1 results
07/24/20 UBS
Roche Q2 sales weak but recovery in June is evident, says UBS
TNDM TNDM
/

+

08/11/20 Piper Sandler
Medtronic acquisition of Companion 'a smart decision,' says Piper Sandler
07/31/20 Craig-Hallum
Tandem Diabetes price target raised to $140 from $102 at Craig-Hallum
07/31/20 Lake Street
Tandem Diabetes price target raised to $137 from $125 at Lake Street
07/31/20 Guggenheim
Guggenheim upgrades Tandem Diabetes to Buy, says tailwinds not fully baked in
TWST Twist Bioscience
$62.31 /

+6.72 (+12.09%)

02/06/20 Cowen
Developments in Agilent-Twist dispute could mean settlement imminent, says Cowen
TXG 10x Genomics
$97.75 /

+0.97 (+1.00%)

08/12/20 JPMorgan
10x Genomics price target raised to $110 from $95 at JPMorgan
07/10/20
Fly Intel: Top five analyst initiations
07/09/20 Stifel
10x Genomics initiated with a Buy at Stifel
05/12/20 Cowen
10x Genomics price target raised to $85 from $68 at Cowen
TXG 10x Genomics
$97.75 /

+0.97 (+1.00%)

TWST Twist Bioscience
$62.31 /

+6.72 (+12.09%)

TNDM TNDM
/

+

RHHBY Roche
$0.00 /

+ (+0.00%)

NVTA Invitae
$29.76 /

+0.775 (+2.67%)

MASI Masimo
$211.09 /

+1.56 (+0.74%)

ILMN Illumina
$344.15 /

+3.03 (+0.89%)

GH Guardant Health
$86.82 /

+5.17 (+6.33%)

BX Blackstone
$52.85 /

+0.38 (+0.72%)

BDX Becton Dickinson
$257.24 /

+2.24 (+0.88%)

ADPT Adaptive Biotechnologies
$38.34 /

+1.56 (+4.24%)

  • 16
    Jul
  • 04
    Jun
  • 02
    Jun
  • 21
    May
  • 02
    Apr
  • 20
    Feb
  • 24
    Jan
  • 12
    Sep
RHHBY Roche
$0.00 /

+ (+0.00%)

MASI Masimo
$211.09 /

+1.56 (+0.74%)

BX Blackstone
$52.85 /

+0.38 (+0.72%)

TXG 10x Genomics
$97.75 /

+0.97 (+1.00%)

TWST Twist Bioscience
$62.31 /

+6.72 (+12.09%)

TNDM TNDM
/

+

RHHBY Roche
$0.00 /

+ (+0.00%)

NVTA Invitae
$29.76 /

+0.775 (+2.67%)

MASI Masimo
$211.09 /

+1.56 (+0.74%)

ILMN Illumina
$344.15 /

+3.03 (+0.89%)

GH Guardant Health
$86.82 /

+5.17 (+6.33%)

BX Blackstone
$52.85 /

+0.38 (+0.72%)

BDX Becton Dickinson
$257.24 /

+2.24 (+0.88%)

ADPT Adaptive Biotechnologies
$38.34 /

+1.56 (+4.24%)

NVTA Invitae
$29.76 /

+0.775 (+2.67%)

ILMN Illumina
$344.15 /

+3.03 (+0.89%)

BX Blackstone
$52.85 /

+0.38 (+0.72%)

Wednesday
Conference/Events
UBS to hold a virtual conference » 04:55
08/12/20
08/12
04:55
08/12/20
04:55
ADPT

Adaptive Biotechnologies

$36.78 /

-0.82 (-2.18%)

, BX

Blackstone

$52.47 /

+0.175 (+0.33%)

, BDX

Becton Dickinson

$255.00 /

-1.75 (-0.68%)

, GH

Guardant Health

$81.65 /

-4.3 (-5.00%)

, ILMN

Illumina

$341.12 /

-12.19 (-3.45%)

, MASI

Masimo

$209.53 /

-1.96 (-0.93%)

, NVTA

Invitae

$28.98 /

+0.17 (+0.59%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, TNDM

TNDM

/

+

, TWST

Twist Bioscience

$55.59 /

-4.17 (-6.98%)

, TXG

10x Genomics

$96.78 /

+0.01 (+0.01%)

Genomics 2.0 Virtual…

Genomics 2.0 Virtual Conference will be held on August 11-13.Webcast Link

ShowHide Related Items >><<
TXG 10x Genomics
$96.78 /

+0.01 (+0.01%)

TWST Twist Bioscience
$55.59 /

-4.17 (-6.98%)

TNDM TNDM
/

+

RHHBY Roche
$0.00 /

+ (+0.00%)

NVTA Invitae
$28.98 /

+0.17 (+0.59%)

MASI Masimo
$209.53 /

-1.96 (-0.93%)

ILMN Illumina
$341.12 /

-12.19 (-3.45%)

GH Guardant Health
$81.65 /

-4.3 (-5.00%)

BX Blackstone
$52.47 /

+0.175 (+0.33%)

BDX Becton Dickinson
$255.00 /

-1.75 (-0.68%)

ADPT Adaptive Biotechnologies
$36.78 /

-0.82 (-2.18%)

ADPT Adaptive Biotechnologies
$36.78 /

-0.82 (-2.18%)

06/18/20 Guggenheim
Adaptive to benefit from increased MRD testing by oncologists, says Guggenheim
06/03/20
Fly Intel: Top five analyst initiations
06/03/20 Goldman Sachs
Adaptive Biotechnologies initiated with a Buy at Goldman Sachs
05/19/20 Guggenheim
Adaptive Biotechnologies price target raised to $50 from $44 at Guggenheim
BX Blackstone
$52.47 /

+0.175 (+0.33%)

06/25/20
Fly Intel: Top five analyst initiations
06/25/20 UBS
Blackstone initiated with a Buy at UBS
06/08/20 Citi
Citi downgrades Alternative Asset Managers to Market Weight, lowers four ratings
06/08/20 Citi
Blackstone downgraded to Neutral from Buy at Citi
BDX Becton Dickinson
$255.00 /

-1.75 (-0.68%)

08/07/20 Raymond James
Becton Dickinson price target raised to $285 from $265 at Raymond James
07/09/20
Fly Intel: Top five analyst upgrades
07/09/20 Barclays
Barclays upgrades Becton Dickinson to Overweight on 'window of opportunity'
07/09/20 Barclays
Becton Dickinson upgraded to Overweight from Equal Weight at Barclays
GH Guardant Health
$81.65 /

-4.3 (-5.00%)

08/10/20 Canaccord
Guardion Health Sciences FDA approval landmark event, says Canaccord
06/12/20
Fly Intel: Top five analyst initiations
06/12/20 BTIG
BTIG starts genomic profiling test 'pioneer' Guardant Health at Buy
06/11/20 BTIG
Guardant Health initiated with a Buy at BTIG
ILMN Illumina
$341.12 /

-12.19 (-3.45%)

08/07/20
Fly Intel: Top five analyst downgrades
08/07/20 Evercore ISI
Illumina downgraded to Underperform from In Line at Evercore ISI
08/07/20 Piper Sandler
Illumina downgraded to Neutral from Overweight at Piper Sandler
07/07/20 Guggenheim
Illumina downgraded to Neutral following 81% rise off lows at Guggenheim
MASI Masimo
$209.53 /

-1.96 (-0.93%)

04/20/20
Fly Intel: Top five analyst downgrades
04/20/20 Needham
Masimo downgraded to Hold from Buy at Needham
04/20/20 Needham
Masimo downgraded to Hold from Buy at Needham
03/02/20 Raymond James
Masimo 'well positioned' should COVID-19 expand, says Raymond James
NVTA Invitae
$28.98 /

+0.17 (+0.59%)

08/05/20 SVB Leerink
Invitae price target lowered to $34 from $40 at SVB Leerink
08/05/20 Ladenburg
Invitae price target raised to $37.25 from $31.25 at Ladenburg
07/22/20 Oppenheimer
Invitae price target raised to $37 from $29 at Oppenheimer
07/01/20 Benchmark
Benchmark says Invitae 'ahead of itself,' downgrades to Hold after run-up
RHHBY Roche
$0.00 /

+ (+0.00%)

07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
07/24/20 Credit Suisse
Credit Suisse backs Neutral on Roche after H1 results
07/24/20 UBS
Roche Q2 sales weak but recovery in June is evident, says UBS
TNDM TNDM
/

+

08/11/20 Piper Sandler
Medtronic acquisition of Companion 'a smart decision,' says Piper Sandler
07/31/20 Craig-Hallum
Tandem Diabetes price target raised to $140 from $102 at Craig-Hallum
07/31/20 Lake Street
Tandem Diabetes price target raised to $137 from $125 at Lake Street
07/31/20 Guggenheim
Guggenheim upgrades Tandem Diabetes to Buy, says tailwinds not fully baked in
TWST Twist Bioscience
$55.59 /

-4.17 (-6.98%)

02/06/20 Cowen
Developments in Agilent-Twist dispute could mean settlement imminent, says Cowen
TXG 10x Genomics
$96.78 /

+0.01 (+0.01%)

07/10/20
Fly Intel: Top five analyst initiations
07/09/20 Stifel
10x Genomics initiated with a Buy at Stifel
05/12/20 Cowen
10x Genomics price target raised to $85 from $68 at Cowen
03/11/20 JPMorgan
JPMorgan continues to recommend select exposure to Life Science Tools
TXG 10x Genomics
$96.78 /

+0.01 (+0.01%)

TWST Twist Bioscience
$55.59 /

-4.17 (-6.98%)

TNDM TNDM
/

+

RHHBY Roche
$0.00 /

+ (+0.00%)

NVTA Invitae
$28.98 /

+0.17 (+0.59%)

MASI Masimo
$209.53 /

-1.96 (-0.93%)

ILMN Illumina
$341.12 /

-12.19 (-3.45%)

GH Guardant Health
$81.65 /

-4.3 (-5.00%)

BX Blackstone
$52.47 /

+0.175 (+0.33%)

BDX Becton Dickinson
$255.00 /

-1.75 (-0.68%)

ADPT Adaptive Biotechnologies
$36.78 /

-0.82 (-2.18%)

  • 16
    Jul
  • 04
    Jun
  • 02
    Jun
  • 21
    May
  • 02
    Apr
  • 20
    Feb
  • 24
    Jan
  • 12
    Sep
RHHBY Roche
$0.00 /

+ (+0.00%)

MASI Masimo
$209.53 /

-1.96 (-0.93%)

BX Blackstone
$52.47 /

+0.175 (+0.33%)

TXG 10x Genomics
$96.78 /

+0.01 (+0.01%)

TWST Twist Bioscience
$55.59 /

-4.17 (-6.98%)

TNDM TNDM
/

+

RHHBY Roche
$0.00 /

+ (+0.00%)

NVTA Invitae
$28.98 /

+0.17 (+0.59%)

MASI Masimo
$209.53 /

-1.96 (-0.93%)

ILMN Illumina
$341.12 /

-12.19 (-3.45%)

GH Guardant Health
$81.65 /

-4.3 (-5.00%)

BX Blackstone
$52.47 /

+0.175 (+0.33%)

BDX Becton Dickinson
$255.00 /

-1.75 (-0.68%)

ADPT Adaptive Biotechnologies
$36.78 /

-0.82 (-2.18%)

NVTA Invitae
$28.98 /

+0.17 (+0.59%)

ILMN Illumina
$341.12 /

-12.19 (-3.45%)

BX Blackstone
$52.47 /

+0.175 (+0.33%)

Tuesday
Conference/Events
UBS to hold a virtual conference » 08:31
08/11/20
08/11
08:31
08/11/20
08:31
ADPT

Adaptive Biotechnologies

$37.60 /

-0.64 (-1.67%)

, BX

Blackstone

$52.30 /

-0.215 (-0.41%)

, BDX

Becton Dickinson

$256.75 /

+0.425 (+0.17%)

, GH

Guardant Health

$85.95 /

+0.16 (+0.19%)

, ILMN

Illumina

$353.31 /

-2.35 (-0.66%)

, MASI

Masimo

$211.49 /

-5.91 (-2.72%)

, NVTA

Invitae

$28.81 /

+0.39 (+1.37%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, TNDM

TNDM

/

+

, TWST

Twist Bioscience

$59.76 /

-1.95 (-3.16%)

, TXG

10x Genomics

$96.77 /

+0.4 (+0.42%)

Genomics 2.0 Virtual…

Genomics 2.0 Virtual Conference will be held on August 11-13.Webcast Link

ShowHide Related Items >><<
TXG 10x Genomics
$96.77 /

+0.4 (+0.42%)

TWST Twist Bioscience
$59.76 /

-1.95 (-3.16%)

TNDM TNDM
/

+

RHHBY Roche
$0.00 /

+ (+0.00%)

NVTA Invitae
$28.81 /

+0.39 (+1.37%)

MASI Masimo
$211.49 /

-5.91 (-2.72%)

ILMN Illumina
$353.31 /

-2.35 (-0.66%)

GH Guardant Health
$85.95 /

+0.16 (+0.19%)

BX Blackstone
$52.30 /

-0.215 (-0.41%)

BDX Becton Dickinson
$256.75 /

+0.425 (+0.17%)

ADPT Adaptive Biotechnologies
$37.60 /

-0.64 (-1.67%)

ADPT Adaptive Biotechnologies
$37.60 /

-0.64 (-1.67%)

06/18/20 Guggenheim
Adaptive to benefit from increased MRD testing by oncologists, says Guggenheim
06/03/20
Fly Intel: Top five analyst initiations
06/03/20 Goldman Sachs
Adaptive Biotechnologies initiated with a Buy at Goldman Sachs
05/19/20 Guggenheim
Adaptive Biotechnologies price target raised to $50 from $44 at Guggenheim
BX Blackstone
$52.30 /

-0.215 (-0.41%)

06/25/20
Fly Intel: Top five analyst initiations
06/25/20 UBS
Blackstone initiated with a Buy at UBS
06/08/20 Citi
Citi downgrades Alternative Asset Managers to Market Weight, lowers four ratings
06/08/20 Citi
Blackstone downgraded to Neutral from Buy at Citi
BDX Becton Dickinson
$256.75 /

+0.425 (+0.17%)

08/07/20 Raymond James
Becton Dickinson price target raised to $285 from $265 at Raymond James
07/09/20
Fly Intel: Top five analyst upgrades
07/09/20 Barclays
Barclays upgrades Becton Dickinson to Overweight on 'window of opportunity'
07/09/20 Barclays
Becton Dickinson upgraded to Overweight from Equal Weight at Barclays
GH Guardant Health
$85.95 /

+0.16 (+0.19%)

08/10/20 Canaccord
Guardion Health Sciences FDA approval landmark event, says Canaccord
06/12/20
Fly Intel: Top five analyst initiations
06/12/20 BTIG
BTIG starts genomic profiling test 'pioneer' Guardant Health at Buy
06/11/20 BTIG
Guardant Health initiated with a Buy at BTIG
ILMN Illumina
$353.31 /

-2.35 (-0.66%)

08/07/20
Fly Intel: Top five analyst downgrades
08/07/20 Evercore ISI
Illumina downgraded to Underperform from In Line at Evercore ISI
08/07/20 Piper Sandler
Illumina downgraded to Neutral from Overweight at Piper Sandler
07/07/20 Guggenheim
Illumina downgraded to Neutral following 81% rise off lows at Guggenheim
MASI Masimo
$211.49 /

-5.91 (-2.72%)

04/20/20
Fly Intel: Top five analyst downgrades
04/20/20 Needham
Masimo downgraded to Hold from Buy at Needham
04/20/20 Needham
Masimo downgraded to Hold from Buy at Needham
03/02/20 Raymond James
Masimo 'well positioned' should COVID-19 expand, says Raymond James
NVTA Invitae
$28.81 /

+0.39 (+1.37%)

08/05/20 SVB Leerink
Invitae price target lowered to $34 from $40 at SVB Leerink
08/05/20 Ladenburg
Invitae price target raised to $37.25 from $31.25 at Ladenburg
07/22/20 Oppenheimer
Invitae price target raised to $37 from $29 at Oppenheimer
07/01/20 Benchmark
Benchmark says Invitae 'ahead of itself,' downgrades to Hold after run-up
RHHBY Roche
$0.00 /

+ (+0.00%)

07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
07/24/20 Credit Suisse
Credit Suisse backs Neutral on Roche after H1 results
07/24/20 UBS
Roche Q2 sales weak but recovery in June is evident, says UBS
TNDM TNDM
/

+

07/31/20 Craig-Hallum
Tandem Diabetes price target raised to $140 from $102 at Craig-Hallum
07/31/20 Lake Street
Tandem Diabetes price target raised to $137 from $125 at Lake Street
07/31/20 Guggenheim
Guggenheim upgrades Tandem Diabetes to Buy, says tailwinds not fully baked in
07/31/20 Guggenheim
Tandem Diabetes upgraded to Buy from Neutral at Guggenheim
TWST Twist Bioscience
$59.76 /

-1.95 (-3.16%)

02/06/20 Cowen
Developments in Agilent-Twist dispute could mean settlement imminent, says Cowen
TXG 10x Genomics
$96.77 /

+0.4 (+0.42%)

07/10/20
Fly Intel: Top five analyst initiations
07/09/20 Stifel
10x Genomics initiated with a Buy at Stifel
05/12/20 Cowen
10x Genomics price target raised to $85 from $68 at Cowen
03/11/20 JPMorgan
JPMorgan continues to recommend select exposure to Life Science Tools
TXG 10x Genomics
$96.77 /

+0.4 (+0.42%)

TWST Twist Bioscience
$59.76 /

-1.95 (-3.16%)

TNDM TNDM
/

+

RHHBY Roche
$0.00 /

+ (+0.00%)

NVTA Invitae
$28.81 /

+0.39 (+1.37%)

MASI Masimo
$211.49 /

-5.91 (-2.72%)

ILMN Illumina
$353.31 /

-2.35 (-0.66%)

GH Guardant Health
$85.95 /

+0.16 (+0.19%)

BX Blackstone
$52.30 /

-0.215 (-0.41%)

BDX Becton Dickinson
$256.75 /

+0.425 (+0.17%)

ADPT Adaptive Biotechnologies
$37.60 /

-0.64 (-1.67%)

  • 16
    Jul
  • 04
    Jun
  • 02
    Jun
  • 21
    May
  • 02
    Apr
  • 20
    Feb
  • 24
    Jan
  • 12
    Sep
RHHBY Roche
$0.00 /

+ (+0.00%)

MASI Masimo
$211.49 /

-5.91 (-2.72%)

BX Blackstone
$52.30 /

-0.215 (-0.41%)

TWST Twist Bioscience
$59.76 /

-1.95 (-3.16%)

TNDM TNDM
/

+

RHHBY Roche
$0.00 /

+ (+0.00%)

NVTA Invitae
$28.81 /

+0.39 (+1.37%)

MASI Masimo
$211.49 /

-5.91 (-2.72%)

ILMN Illumina
$353.31 /

-2.35 (-0.66%)

GH Guardant Health
$85.95 /

+0.16 (+0.19%)

BX Blackstone
$52.30 /

-0.215 (-0.41%)

BDX Becton Dickinson
$256.75 /

+0.425 (+0.17%)

ADPT Adaptive Biotechnologies
$37.60 /

-0.64 (-1.67%)

NVTA Invitae
$28.81 /

+0.39 (+1.37%)

ILMN Illumina
$353.31 /

-2.35 (-0.66%)

BX Blackstone
$52.30 /

-0.215 (-0.41%)

Hot Stocks
LabCorp to perform no-charge COVID-19 antibody test to increase plasma donations » 07:11
08/11/20
08/11
07:11
08/11/20
07:11
LH

LabCorp

$187.21 /

-5.83 (-3.02%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

LabCorp (LH) announced…

LabCorp (LH) announced details of a no-charge antibody testing program in response to federal health authorities' request to increase donations of COVID-19 blood plasma. Plasma with COVID-19 antibodies may be helpful when treating patients with an active COVID-19 infection and is being evaluated as a possible treatment. For the next three months, LabCorp will perform the high-affinity antibody test at no charge to patients, insurance companies, or the government. When patients are receiving other medically necessary blood tests as part of a medically necessary exam or treatment, this program allows providers to add the SARS-CoV-2 Antibodies Test to the same order at no charge. The no-charge high-affinity antibody testing program will use only the Roche (RHHBY) Elecsys Anti-SARS-CoV-2 and does not apply to other COVID-19 antibody tests, such as the IgG test. Patients will be able to access their results through the LabCorp Patient portal and through their doctor. Result data from the antibody testing program will also be reported to the CDC and state public health agencies to further support COVID-19 surveillance and response efforts.

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

LH LabCorp
$187.21 /

-5.83 (-3.02%)

LH LabCorp
$187.21 /

-5.83 (-3.02%)

07/31/20 Mizuho
LabCorp price target raised to $215 from $186 at Mizuho
07/29/20 Truist
LabCorp price target raised to $240 from $220 at SunTrust
07/29/20 Deutsche Bank
LabCorp price target raised to $230 from $210 at Deutsche Bank
07/29/20 Citi
LabCorp price target raised to $249 from $214 at Citi
RHHBY Roche
$0.00 /

+ (+0.00%)

07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
07/24/20 Credit Suisse
Credit Suisse backs Neutral on Roche after H1 results
07/24/20 UBS
Roche Q2 sales weak but recovery in June is evident, says UBS
RHHBY Roche
$0.00 /

+ (+0.00%)

LH LabCorp
$187.21 /

-5.83 (-3.02%)

RHHBY Roche
$0.00 /

+ (+0.00%)

LH LabCorp
$187.21 /

-5.83 (-3.02%)

RHHBY Roche
$0.00 /

+ (+0.00%)

LH LabCorp
$187.21 /

-5.83 (-3.02%)

LH LabCorp
$187.21 /

-5.83 (-3.02%)

Hot Stocks
Bicycle Therapeutics appoints Dominc Smethurst as Chief Medical Officer » 07:02
08/11/20
08/11
07:02
08/11/20
07:02
BCYC

Bicycle Therapeutics

$15.92 /

+0.09 (+0.57%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, AZN

AstraZeneca

$55.40 /

-0.005 (-0.01%)

, AMGN

Amgen

$238.12 /

-2.45 (-1.02%)

, ADAP

Adaptimmune

$8.28 /

+0.32 (+4.02%)

Bicycle Therapeutics…

Bicycle Therapeutics (BCYC) announced the appointment of Dominic Smethurst, as Chief Medical Officer. Smethurst brings to Bicycle extensive expertise in developing bispecific immuno-oncology agents, as well as toxin conjugate therapeutics for cancer and other serious diseases. Dominic Smethurst has over twenty years of experience working with leading pharmaceutical and biotechnology companies, clinical research institutions, and the UK's National Health Service. He was most recently a medical consultant, advising biopharma companies on clinical development strategies and licensing projects. Prior to that, he served as Chief Medical Officer of Tusk Therapeutics, an immuno-oncology company acquired by Roche (RHHBY), where he oversaw development of antibodies targeting CD25 and CD137, among others. Previously, as Vice President Oncology and Global Therapeutic Area Lead at Icon, a global contract research organization, he executed clinical trials involving numerous novel cancer treatments, including CAR-T therapies. Prior to that, Smethurst held physician leadership roles at AstraZeneca (AZN), Amgen (AMGN) and Adaptimmune (ADAP).

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

BCYC Bicycle Therapeutics
$15.92 /

+0.09 (+0.57%)

AZN AstraZeneca
$55.40 /

-0.005 (-0.01%)

AMGN Amgen
$238.12 /

-2.45 (-1.02%)

ADAP Adaptimmune
$8.28 /

+0.32 (+4.02%)

BCYC Bicycle Therapeutics
$15.92 /

+0.09 (+0.57%)

06/11/20 Oppenheimer
Oppenheimer starts 'revolutionary' Bicycle Therapeutics at Outperform
06/11/20 Oppenheimer
Bicycle Therapeutics initiated with an Outperform at Oppenheimer
04/17/20
Fly Intel: Top five analyst initiations
04/17/20 H.C. Wainwright
Bicycle Therapeutics initiated with a Buy at H.C. Wainwright
RHHBY Roche
$0.00 /

+ (+0.00%)

07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
07/24/20 Credit Suisse
Credit Suisse backs Neutral on Roche after H1 results
07/24/20 UBS
Roche Q2 sales weak but recovery in June is evident, says UBS
AZN AstraZeneca
$55.40 /

-0.005 (-0.01%)

08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/31/20 Barclays
Barclays backs Overweight on AstraZeneca after Q2 results
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
AMGN Amgen
$238.12 /

-2.45 (-1.02%)

07/29/20 Piper Sandler
Piper says AbbVie's atogepant 'may yet emerge as best in class'
07/29/20 SVB Leerink
Amgen price target raised to $261 from $253 at SVB Leerink
07/29/20 Wells Fargo
Amgen price target raised to $247 from $237 at Wells Fargo
07/29/20 RBC Capital
Amgen price target lowered to $223 from $236 at RBC Capital
ADAP Adaptimmune
$8.28 /

+0.32 (+4.02%)

06/01/20 Mizuho
Adaptimmune price target raised to $9 from $3 at Mizuho
05/29/20 JonesTrading
JonesTrading upgrades Adaptimmune to Buy after data alleviates 'key concern'
05/29/20 JonesTrading
Adaptimmune upgraded to Buy from Hold at JonesTrading
05/29/20 Mizuho
Adaptimmune data 'incrementally supportive,' but still early, says Mizuho
RHHBY Roche
$0.00 /

+ (+0.00%)

BCYC Bicycle Therapeutics
$15.92 /

+0.09 (+0.57%)

AZN AstraZeneca
$55.40 /

-0.005 (-0.01%)

AMGN Amgen
$238.12 /

-2.45 (-1.02%)

ADAP Adaptimmune
$8.28 /

+0.32 (+4.02%)

  • 02
    Jun
  • 22
    Jan
RHHBY Roche
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$55.40 /

-0.005 (-0.01%)

AMGN Amgen
$238.12 /

-2.45 (-1.02%)

RHHBY Roche
$0.00 /

+ (+0.00%)

BCYC Bicycle Therapeutics
$15.92 /

+0.09 (+0.57%)

AZN AstraZeneca
$55.40 /

-0.005 (-0.01%)

AMGN Amgen
$238.12 /

-2.45 (-1.02%)

ADAP Adaptimmune
$8.28 /

+0.32 (+4.02%)

AZN AstraZeneca
$55.40 /

-0.005 (-0.01%)

AMGN Amgen
$238.12 /

-2.45 (-1.02%)

ADAP Adaptimmune
$8.28 /

+0.32 (+4.02%)

Monday
Hot Stocks
Spark Therapeutics appoints Gallia Levy as CMO » 08:31
08/10/20
08/10
08:31
08/10/20
08:31
RHHBY

Roche

$0.00 /

+ (+0.00%)

Spark Therapeutics…

Spark Therapeutics announced the appointment of Gallia Levy, M.D., Ph.D., as chief medical officer. Dr. Levy will be responsible for strategic and operational leadership across all functions in the product development lifecycle, including setting the global development strategy for current and future pipeline programs. Levy joins Spark Therapeutics from Genentech, also a member of the Roche Group, where she served as the Vice President and Global Head of the Rare Blood Disorders franchise in Product Development.

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
07/24/20 Credit Suisse
Credit Suisse backs Neutral on Roche after H1 results
07/24/20 UBS
Roche Q2 sales weak but recovery in June is evident, says UBS
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

Hot Stocks
Genentech says etrolizumab trial met one primary endpoint, failed to meet other » 05:14
08/10/20
08/10
05:14
08/10/20
05:14
RHHBY

Roche

$0.00 /

+ (+0.00%)

Genentech, a member of…

Genentech, a member of the Roche Group, announced topline results from its Phase III study program evaluating the investigational medicine etrolizumab in people with moderately to severely active ulcerative colitis. Genentech said in a release, "Mixed results were seen in studies evaluating etrolizumab as an induction therapy, and both studies evaluating etrolizumab as a maintenance therapy failed to meet their primary endpoints, showing no significant difference in the proportion of people achieving remission with subcutaneous etrolizumab versus placebo. In the HIBISCUS I induction study, in people without prior anti-tumor necrosis factor (anti-TNF) treatment, etrolizumab met the primary endpoint. In contrast, the HIBISCUS II induction study, which also included people without prior anti-TNF treatment, did not meet its primary endpoint. In the HICKORY study, in people with prior anti-TNF treatment, etrolizumab met the primary endpoint at induction but not at maintenance. In the LAUREL maintenance study in people without prior anti-TNF treatment, etrolizumab failed to meet its primary endpoint. The safety profile of etrolizumab was consistent with previous studies and no major safety issues were identified in the four Phase III clinical trials reported to date. Further analyses of the data, including secondary endpoints, are ongoing and will be submitted for presentation at upcoming medical meetings. Etrolizumab continues to be studied as an investigational induction and maintenance treatment in people with moderately to severely active Crohn's disease with and without prior anti-TNF treatment in a global Phase III study (BERGAMOT) and open-label extension and safety monitoring study (JUNIPER), involving more than 1,100 people with Crohn's disease. In addition, Genentech is studying other investigational medicines in inflammatory bowel diseases and is committed to further understanding this disease."

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
07/24/20 Credit Suisse
Credit Suisse backs Neutral on Roche after H1 results
07/24/20 UBS
Roche Q2 sales weak but recovery in June is evident, says UBS
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

Saturday
On The Fly
Week in review: How Trump's policies moved stocks » 07:32
08/08/20
08/08
07:32
08/08/20
07:32
TCEHY

Tencent

$0.00 /

+ (+0.00%)

, MSFT

Microsoft

$212.45 /

-3.87 (-1.79%)

, AZN

AstraZeneca

$55.40 /

-0.8 (-1.42%)

, BMY

Bristol-Myers

$61.03 /

-0.27 (-0.44%)

, LLY

Eli Lilly

$152.89 /

+0.01 (+0.01%)

, GSK

GlaxoSmithKline

$40.79 /

-0.185 (-0.45%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, KODK

Eastman Kodak

$14.88 /

-1.195 (-7.43%)

, AA

Alcoa

$14.67 /

-0.22 (-1.48%)

, CENX

Century Aluminum

$10.53 /

-0.06 (-0.57%)

, KALU

Kaiser Aluminum

$66.81 /

+0.49 (+0.74%)

, ARNC

Arconic

$19.94 /

-0.395 (-1.94%)

, FB

Facebook

$268.52 /

+3.295 (+1.24%)

, TWTR

Twitter

$37.14 /

-0.55 (-1.46%)

Catch up on the top…

Open Full Text

ShowHide Related Items >><<
TWTR Twitter
$37.14 /

-0.55 (-1.46%)

TCEHY Tencent
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MSFT Microsoft
$212.45 /

-3.87 (-1.79%)

LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

KODK Eastman Kodak
$14.88 /

-1.195 (-7.43%)

KALU Kaiser Aluminum
$66.81 /

+0.49 (+0.74%)

GSK GlaxoSmithKline
$40.79 /

-0.185 (-0.45%)

FB Facebook
$268.52 /

+3.295 (+1.24%)

CENX Century Aluminum
$10.53 /

-0.06 (-0.57%)

BMY Bristol-Myers
$61.03 /

-0.27 (-0.44%)

AZN AstraZeneca
$55.40 /

-0.8 (-1.42%)

ARNC Arconic
$19.94 /

-0.395 (-1.94%)

AA Alcoa
$14.67 /

-0.22 (-1.48%)

TCEHY Tencent
$0.00 /

+ (+0.00%)

08/03/20 Morgan Stanley
Sohu.com named a Research Tactical Idea at Morgan Stanley
07/27/20 Barclays
Tencent price target raised to $75 from $63 at Barclays
07/14/20 Citi
Tencent price target raised to HK$649 from HK$541 at Citi
07/08/20 Mizuho
Tencent price target raised to HK$475 from HK$410 at Mizuho
MSFT Microsoft
$212.45 /

-3.87 (-1.79%)

08/07/20 DA Davidson
Datadog price target raised to $80 from $52 at DA Davidson
08/05/20 Morgan Stanley
Morgan Stanley says TikTok US operations could be 'compelling' fit for Microsoft
08/04/20 Wedbush
Wedbush sees 75%-80% chance of Microsoft buying TikTok's U.S. operations
08/04/20 Oppenheimer
TikTok presents 'unique opportunity' for Microsoft, says Oppenheimer
AZN AstraZeneca
$55.40 /

-0.8 (-1.42%)

08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/31/20 Barclays
Barclays backs Overweight on AstraZeneca after Q2 results
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
BMY Bristol-Myers
$61.03 /

-0.27 (-0.44%)

08/06/20 Citi
Investors can refocus on Bristol-Myers story after Eliquis win, says Citi
07/28/20 Mizuho
Wait for Bristol-Myers' bb2121 submission making some 'nervous,' says Mizuho
07/28/20
Fly Intel: Top five analyst initiations
07/28/20 Raymond James
Bristol-Myers initiated with an Outperform at Raymond James
LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

07/31/20 Barclays
Eli Lilly earnings selloff 'meaningful over-reaction,' says Barclays
07/15/20 H.C. Wainwright
Blueprint Medicines price target raised to $110 from $66 at H.C. Wainwright
07/14/20 Baird
Blueprint Medicines price target raised to $100 from $90 at Baird
07/14/20 Raymond James
Blueprint Medicines price target raised to $106 from $95 at Raymond James
GSK GlaxoSmithKline
$40.79 /

-0.185 (-0.45%)

07/31/20 Barclays
Barclays backs Underweight on GSK after 'challenging' Q2
07/30/20 Roth Capital
Roth Capital bullish on Ideaya as GSK highlights synthetic lethality pipeline
07/13/20 UBS
UBS reiterates Buy on GSK as FDA belantamab docs are out
07/13/20 JPMorgan
Ideaya upgraded to Overweight on recent pullback at JPMorgan
RHHBY Roche
$0.00 /

+ (+0.00%)

07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
07/24/20 Credit Suisse
Credit Suisse backs Neutral on Roche after H1 results
07/24/20 UBS
Roche Q2 sales weak but recovery in June is evident, says UBS
KODK Eastman Kodak
$14.88 /

-1.195 (-7.43%)

AA Alcoa
$14.67 /

-0.22 (-1.48%)

07/16/20 B. Riley FBR
Alcoa price target raised to $11 from $9 at B. Riley FBR
06/16/20
Fly Intel: Top five analyst downgrades
06/16/20 Deutsche Bank
Alcoa downgraded to Hold with $10 price target at Deutsche Bank
06/15/20 Deutsche Bank
Alcoa downgraded to Hold from Buy at Deutsche Bank
CENX Century Aluminum
$10.53 /

-0.06 (-0.57%)

06/25/20 BMO Capital
Century Aluminum downgraded to Market Perform from Outperform at BMO Capital
06/09/20 B. Riley FBR
B. Riley FBR downgrades Contura Energy after liquidity stress test
03/24/20 B. Riley FBR
Century Aluminum downgraded to Neutral from Buy at B. Riley FBR
12/20/19 B. Riley FBR
Alcoa price target lowered to $25 from $28 at B. Riley FBR
KALU Kaiser Aluminum
$66.81 /

+0.49 (+0.74%)

01/16/20 Benchmark
Kaiser Aluminum initiated with a Hold at Benchmark
ARNC Arconic
$19.94 /

-0.395 (-1.94%)

05/20/20
Fly Intel: Top five analyst initiations
05/20/20 Credit Suisse
Arconic initiated with an Outperform at Credit Suisse
04/01/20 Cowen
Howmet Aerospace price target lowered to $17 from $23 at Cowen
03/20/20 Barclays
Arconic downgraded to Equal Weight from Overweight at Barclays
FB Facebook
$268.52 /

+3.295 (+1.24%)

08/10/20 Truist
Trade Desk price target raised to $450 from $250 at Truist
08/10/20 Morgan Stanley
Pinterest upgraded to Overweight on social shopping trend at Morgan Stanley
08/10/20 Mizuho
Facebook price target raised to $315 from $285 at Mizuho
08/05/20 HSBC
HSBC bumps up Facebook target to $195, maintains Reduce rating
TWTR Twitter
$37.14 /

-0.55 (-1.46%)

07/28/20 Morgan Stanley
Morgan Stanley lowers near-term, long-term forecasts for Roku
07/24/20 Truist
Twitter price target raised to $40 from $32 at SunTrust
07/24/20 Argus
Twitter price target raised to $46 from $40 at Argus
07/24/20 Canaccord
Twitter price target raised to $40 from $32 at Canaccord
TWTR Twitter
$37.14 /

-0.55 (-1.46%)

TCEHY Tencent
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MSFT Microsoft
$212.45 /

-3.87 (-1.79%)

LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

KALU Kaiser Aluminum
$66.81 /

+0.49 (+0.74%)

GSK GlaxoSmithKline
$40.79 /

-0.185 (-0.45%)

FB Facebook
$268.52 /

+3.295 (+1.24%)

CENX Century Aluminum
$10.53 /

-0.06 (-0.57%)

BMY Bristol-Myers
$61.03 /

-0.27 (-0.44%)

AZN AstraZeneca
$55.40 /

-0.8 (-1.42%)

ARNC Arconic
$19.94 /

-0.395 (-1.94%)

AA Alcoa
$14.67 /

-0.22 (-1.48%)

TWTR Twitter
$37.14 /

-0.55 (-1.46%)

TCEHY Tencent
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MSFT Microsoft
$212.45 /

-3.87 (-1.79%)

LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

KODK Eastman Kodak
$14.88 /

-1.195 (-7.43%)

GSK GlaxoSmithKline
$40.79 /

-0.185 (-0.45%)

FB Facebook
$268.52 /

+3.295 (+1.24%)

BMY Bristol-Myers
$61.03 /

-0.27 (-0.44%)

AZN AstraZeneca
$55.40 /

-0.8 (-1.42%)

AA Alcoa
$14.67 /

-0.22 (-1.48%)

TWTR Twitter
$37.14 /

-0.55 (-1.46%)

TCEHY Tencent
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MSFT Microsoft
$212.45 /

-3.87 (-1.79%)

LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

KODK Eastman Kodak
$14.88 /

-1.195 (-7.43%)

GSK GlaxoSmithKline
$40.79 /

-0.185 (-0.45%)

FB Facebook
$268.52 /

+3.295 (+1.24%)

BMY Bristol-Myers
$61.03 /

-0.27 (-0.44%)

AZN AstraZeneca
$55.40 /

-0.8 (-1.42%)

ARNC Arconic
$19.94 /

-0.395 (-1.94%)

AA Alcoa
$14.67 /

-0.22 (-1.48%)

TWTR Twitter
$37.14 /

-0.55 (-1.46%)

MSFT Microsoft
$212.45 /

-3.87 (-1.79%)

LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

KODK Eastman Kodak
$14.88 /

-1.195 (-7.43%)

GSK GlaxoSmithKline
$40.79 /

-0.185 (-0.45%)

FB Facebook
$268.52 /

+3.295 (+1.24%)

BMY Bristol-Myers
$61.03 /

-0.27 (-0.44%)

AZN AstraZeneca
$55.40 /

-0.8 (-1.42%)

ARNC Arconic
$19.94 /

-0.395 (-1.94%)

AA Alcoa
$14.67 /

-0.22 (-1.48%)

MSFT Microsoft
$212.45 /

-3.87 (-1.79%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.